image
Healthcare - Biotechnology - NASDAQ - US
$ 1.07
0 %
$ 64.8 M
Market Cap
-0.55
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ABOS stock under the worst case scenario is HIDDEN Compared to the current market price of 1.07 USD, Acumen Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ABOS stock under the base case scenario is HIDDEN Compared to the current market price of 1.07 USD, Acumen Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one ABOS stock under the best case scenario is HIDDEN Compared to the current market price of 1.07 USD, Acumen Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ABOS

image
$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.815 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-114 M OPERATING INCOME
-86.49%
-102 M NET INCOME
-95.39%
-86.2 M OPERATING CASH FLOW
-100.20%
48 M INVESTING CASH FLOW
127.98%
6.93 M FINANCING CASH FLOW
-95.43%
0 REVENUE
0.00%
-30.4 M OPERATING INCOME
23.30%
-28.8 M NET INCOME
22.50%
-34.1 M OPERATING CASH FLOW
-25.38%
28.7 M INVESTING CASH FLOW
-3.28%
-36 K FINANCING CASH FLOW
-300.00%
Balance Sheet Acumen Pharmaceuticals, Inc.
image
Current Assets 178 M
Cash & Short-Term Investments 172 M
Receivables 398 K
Other Current Assets 6.35 M
Non-Current Assets 60.7 M
Long-Term Investments 60 M
PP&E 339 K
Other Non-Current Assets 379 K
71.78 %25.09 %Total Assets$239.0m
Current Liabilities 27.6 M
Accounts Payable 5.65 M
Short-Term Debt 266 K
Other Current Liabilities 21.7 M
Non-Current Liabilities 29.6 M
Long-Term Debt 29.6 M
Other Non-Current Liabilities 0
9.88 %37.94 %51.72 %Total Liabilities$57.2m
EFFICIENCY
Earnings Waterfall Acumen Pharmaceuticals, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 114 M
Operating Income -114 M
Other Expenses -11.7 M
Net Income -102 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)000(114m)(114m)12m(102m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-56.28% ROE
-56.28%
-42.82% ROA
-42.82%
-53.87% ROIC
-53.87%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Acumen Pharmaceuticals, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)202020202021202120222022202320232024202420252025
Net Income -102 M
Depreciation & Amortization 178 K
Capital Expenditures -16 K
Stock-Based Compensation 9.64 M
Change in Working Capital 11.7 M
Others 2.03 M
Free Cash Flow -86.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Acumen Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for ABOS of $7 , with forecasts ranging from a low of $7 to a high of $7 .
ABOS Lowest Price Target Wall Street Target
7 USD 554.21%
ABOS Average Price Target Wall Street Target
7 USD 554.21%
ABOS Highest Price Target Wall Street Target
7 USD 554.21%
Price
Max Price Target
Min Price Target
Average Price Target
7766554433221100Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Acumen Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
259 K USD 5
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and CBO Dr. Jim Doherty - President and CDO Dr. Eric Siemers - Chief Medical Officer Conference Call Participants Sarah Medeiros - Cantor Fitzgerald Tom Shrader - BTIG Ting Liu - UBS Operator Good day and thank you for standing by. Welcome to the Acumen Pharmaceuticals Q1 2025 Conference Call and Webcast. seekingalpha.com - 1 month ago
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET. globenewswire.com - 1 month ago
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2025 financial results on Tuesday, May 13, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. globenewswire.com - 1 month ago
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease globenewswire.com - 2 months ago
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and Chief Business Officer Jim Doherty - President and Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - Bank of America Pete Stavropoulos - Cantor Fitzgerald Ting Liu - UBS Tom Shrader - BTIG Ananda Ghosh - H. C. Wainwright & Company Operator Good day and welcome to Acumen Pharma Fiscal Year 2024 Conference Call and Webcast. seekingalpha.com - 2 months ago
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update. globenewswire.com - 2 months ago
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today's Marketplace host Elizabeth Hart to discuss Alzheimer's Disease. globenewswire.com - 2 months ago
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug globenewswire.com - 3 months ago
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences NEWTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in webcast fireside chats at two upcoming investor conferences: globenewswire.com - 3 months ago
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET. globenewswire.com - 6 months ago
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Braun - Head of Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer, Chief Business Officer Dr. Jim Doherty - President, Chief Development Officer Dr. Eric Siemers - Chief Medical Officer. Conference Call Participants Mark Hitrik - Stifel Tom Shrader - BTIG Cameron Bozdog - BofA Securities Samantha Schaeffer - Cantor Fitzgerald Operator Hello, and welcome to Acumen Pharmaceuticals Q3 2024 Conference Call and Webcast. seekingalpha.com - 7 months ago
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Stifel Healthcare Conference on Monday, Nov. 18, 2024, at 11:30 a.m. ET. globenewswire.com - 7 months ago
8. Profile Summary

Acumen Pharmaceuticals, Inc. ABOS

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 64.8 M
Dividend Yield 0.00%
Description Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Contact 427 Park Street, Newton, VA, 22902 https://acumenpharm.com
IPO Date July 1, 2021
Employees 61
Officers Ms. Alex Braun M.B.A. Vice President & Head of Investor Relations Ms. Kelly Carranza Vice President, Finance & Accounting and Corporate Controller Dr. Caleb E. Finch Ph.D. Co-Founder Mr. Matt Zuga Chief Financial Officer & Chief Business Officer Mr. Daniel J. O'Connell M.B.A. Chief Executive Officer & Director Mr. Derek M. Meisner Esq., J.D. Chief Legal Officer & Corporate Secretary Dr. William L. Klein Ph.D. Co-Founder Dr. James Doherty Ph.D. President & Chief Development Officer Dr. Grant A. Krafft Ph.D. Co-Founder Mr. Russell Barton M.S. Chief Operating Officer